Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 1 Jan 2012

Funakoshi-Tago Megumi

Abstract excerpt

Janus kinase 2 (JAK2) is an essential non-receptor type tyrosine kinase for various cytokine signals. In 2005, a somatic JAK2 mutation (V617F) was found in the majority of myeloproliferative neoplasm (MPN) patients. It has been shown that the V617F mutation caused the constitutive activation of J...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinase A
Share to Carcinogenesis
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematologic Neoplasms

Share to Janus Kinase 2

Share to Myeloproliferative Disorders

Share to Ornithine Decarboxylase

Share to Proto-Oncogene Proteins c-myc

Source

Identifiers

PMID: 23123718
DOI: 10.1248/yakushi.12-00225

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23123718-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].PMID 23123718Read ↗

[Research advances in the role of JAK2 mutations in acute leukemia].Semantic proximity Read ↗

[Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].Semantic proximity Read ↗

JAK2 as a molecular marker in myeloproliferative diseases.Semantic proximity Read ↗

[Abnormal activation of tyrosine kinases and its role in the pathogenesis of hematological malignancies - review].Semantic proximity Read ↗

[JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation].Semantic proximity Read ↗

Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.Semantic proximity Read ↗

[Construction of a Mouse Model for Myeloproliferative Neoplasms and an Evaluation System].Semantic proximity Read ↗

Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm.Semantic proximity Read ↗

Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant stateSemantic proximity Read ↗

A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemiaSemantic proximity Read ↗

[Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].Semantic proximity Read ↗

Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.